Compare BTDR & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BTDR | ICUI |
|---|---|---|
| Founded | 2021 | 1984 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.6B |
| IPO Year | 2021 | 1995 |
| Metric | BTDR | ICUI |
|---|---|---|
| Price | $12.55 | $159.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 3 |
| Target Price | $22.70 | ★ $169.00 |
| AVG Volume (30 Days) | ★ 9.4M | 278.8K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.62 |
| EPS | N/A | ★ 1.20 |
| Revenue | N/A | ★ $2,231,262,000.00 |
| Revenue This Year | $72.51 | N/A |
| Revenue Next Year | $40.84 | $4.46 |
| P/E Ratio | ★ N/A | $127.54 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.04 | $107.02 |
| 52 Week High | $27.80 | $162.18 |
| Indicator | BTDR | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 38.68 | 63.11 |
| Support Level | $12.08 | $143.05 |
| Resistance Level | $12.86 | $160.78 |
| Average True Range (ATR) | 1.54 | 5.48 |
| MACD | -0.41 | 0.20 |
| Stochastic Oscillator | 10.82 | 82.41 |
Bitdeer Technologies Group is principally engaged in the provision of digital asset mining services. The Company does not conduct any substantive operations on its own but conducts its primary operations through its subsidiaries. Its majority business segments are: proprietary mining, cloud hash rate sharing and cloud hosting. The company operates five proprietary mining datacenters in the United States and Norway, Bhutan and Singapore.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.